News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>BOCOMI: Many CN Innovative Drugs to Announce Blockbuster Data at ASCO Meeting w/ Record High No. of Selected CN Innovative Drug
The H shares of pharma inclined today (29th). SINO BIOPHARM (01177.HK) advanced 5.5% to $4.42, while CSPC PHARMA (01093.HK) surged 11.6% after announcing its 1Q results. AKESO (099...
Reset
Send
The window will close in 5 seconds
<Research>BOCOMI: Many CN Innovative Drugs to Announce Blockbuster Data at ASCO Meeting w/ Record High No. of Selected CN Innovative Drug
Close
Recommend
59
Positive
95
Negative
42
 
SHORT SELL
 
STOCK INFO

The H shares of pharma inclined today (29th). SINO BIOPHARM (01177.HK)  -0.030 (-0.397%)    Short selling $372.91M; Ratio 17.673%   advanced 5.5% to $4.42, while CSPC PHARMA (01093.HK)  +0.230 (+2.330%)    Short selling $889.14M; Ratio 19.722%   surged 11.6% after announcing its 1Q results. AKESO (09926.HK)  -2.800 (-1.799%)    Short selling $253.56M; Ratio 11.035%   leaped 4%, while WUXI APPTEC (02359.HK)  +0.300 (+0.269%)    Short selling $457.46M; Ratio 20.855%   swelled 6.6%. WUXI BIO (02269.HK)  -0.100 (-0.298%)    Short selling $471.56M; Ratio 11.189%   shot up 9.8%.

The 2025 annual meeting of American Society of Clinical Oncology (ASCO) will be held from 30 May to 3 June in Chicago, the US, BOCOMI released a research report saying.

Related NewsCICC Lists HK Stocks w/ Largest QoQ Gains in Holdings by CN Actively Managed Equity Funds (Table)
On 22 May, the full abstract of the ASCO annual meeting was released, in which a number of innovative drug companies, including HENGRUI PHARMA (01276.HK)  -2.450 (-2.995%)   , INNOVENT BIO (01801.HK)  -1.500 (-1.501%)    Short selling $513.45M; Ratio 9.499%   , REMEGEN (09995.HK)  -5.300 (-7.571%)    Short selling $37.11M; Ratio 4.661%   , Chia Tai Tianqing and SKB BIO-B (06990.HK)  -5.600 (-1.421%)    Short selling $42.11M; Ratio 6.964%   , presented excellent clinical data.

The number of Chinese innovative drugs selected in the abstract of 2025 ASCO annual meeting reached another new high, confirming that Chinese innovative drug companies achieved a leapfrog breakthrough in research & development competitiveness, with gradually increasing international influence, BOCOMI added.

Considering the significant investment cost-performance ratio (CP ratio) of the sector, low institutional positions and continuous implementation of favorable policies related to the support of innovative drugs throughout the chain, the broker suggested that short-term focus can be placed on ANTENGENE-B (06996.HK)  +0.100 (+1.779%)   and other innovative drug stocks with rich short-term catalysts, high earnings growth or break-even point and greater flexibility in valuation; prescription drug companies with high performance growth + valuation multiple expansion potential, such as SIMCERE PHARMA (02096.HK)  -0.600 (-4.202%)    Short selling $35.02M; Ratio 8.228%   and HANSOH PHARMA (03692.HK)  -0.850 (-2.282%)    Short selling $110.88M; Ratio 21.002%   , etc..
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-30 16:25.)

Related NewsM Stanley Rates WUXI BIO as Overweight w/ TP HKD35; Positive Profit Alert Beats

AAStocks Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.